Protocols

Buyout buzz centers on a Novartis NASH deal for Genfit; Synthon joins the CD47 club

→ Genfit $GNFT has become the target of the latest round of M&A rumors. StreetInsider says that Novartis is close to a deal to acquire France’s Genfit, which has been working on a new drug for NASH, now in Phase III.

→ You can welcome the Dutch biotech Synthon to the ranks of CD47 drug developers. Synthon has licensed worldwide rights to Sanquin’s lead antibodies and IP regarding the CD47-SIRPα pathway to develop new immuno-oncology treatments.

→ Dublin-based Prothena {PRTA} has sold 2,700,000 of its ordinary shares at a price to the public of $57.50 per ordinary share.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->